BioSpace News Archive

Drug Development

SignalRx to Present on its First-In-Class Triple CDK4-6/PI3K/BRD4 Inhibitor SRX3177 for Treating Cancer at the 13th Annual Drug Discovery Chemistry 2018 Meeting

SignalRx Pharmaceuticals Inc., a clinical-stage company developing novel small-molecules therapeutics via in-silico design to simultaneously inhibit multiple key orthogonal and synergistic oncotargets for the treatment of cancer, today announced the presentation of its novel triple CDK4-6/PI3K/BRD4 inhibitor program and first-in-class triple inhibitor SRX3177.

April 5, 2018
·
3 min read
Biotech Beach

SignalRx announces its proprietary small molecule dual inhibitor of PI3K and BRD4, SF2523, demonstrates “Shock and Kill” effects on latent HIV virus as a promising approach to curing AIDS

SignalRx Pharmaceuticals Inc., a clinical-stage company developing novel small-molecules therapeutics to inhibit key orthogonal and synergistic oncotargets for the treatment of cancer, today announced the publication in the Journal of Biological Chemistry studies demonstrating its dual PI3K/BRD4 inhibitor SF2523 suppresses HIV-1 replication and eliminates the latent infectious state.

April 5, 2018
·
2 min read
Career Advice

How to Ask For a Promotion and Actually Get It!

Securing a promotion is a goal that many life science professionals have to progress their career. Whether it’s becoming a laboratory manager or lead scientist, getting promoted within your organization is a way to show your value.

April 5, 2018
·
4 min read
·
Porschia Parker